Contrast-induced nephropathy prevention by remote ischemic preconditioning: Effect of diabetes mellitus

We read with great interest the paper by Moretti et al. [1] published in IJC in April 1, 2018. They included 107 remote ischemic preconditioning (RIPC) treated patients with coronary artery disease (CAD) [stable 50, acute coronary syndrome (ACS) 57] and 116 sham controls (stable 62, ACS 54) undergoing percutaneous coronary intervention (PCI). Based on the subgroup analysis of diabetes status, they arbitrarily concluded that the contrast-induced nephropathy (CIN) prevention by RIPC may be more pronounced in the non-diabetes group than in diabetes group.

Source: International Journal of Cardiology - July 22, 2018 Category: Cardiology Authors: Baohui Lou, Haiyang Gao Tags: Letter to the Editor Source Type: research